Preliminary study of pirmenol in the treatment of ventricular arrhythmias.
The effects of pirmenol in the treatment of ventricular arrhythmias were studied in 6 patients with heart disease and in 11 control subjects. In the patients with heart disease, ventricular arrhythmias were associated with myocardial infarction in 3, with mild aortic stenosis in 2 and with hypertrophic cardiomyopathy in 1. Pirmenol was administered in a 100 mg, 150 mg or 200 mg twice daily dosing schedule. Dosages were increased if necessary, until response, defined as greater than 70% suppression in the rate of premature ventricular contractions, occurred. Arrhythmia suppression was maintained in all 6 patients with heart disease at 52 weeks of follow-up.
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006331:Heart Diseases / Q000150:complications; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D010880:Piperidines; C024318:pirmenol